Please login to the form below

Not currently logged in
Email:
Password:

Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment

Pfizer

Pfizer’s Ibrance has been approved by the National Institute for Health and Care Excellence (NICE) in England through its Cancer Drugs Fund as a second-line treatment for advanced breast cancer.

Ibrance (palbociclib), in combination with fluvestrant has been approved for use via the Cancer Drugs Fund in women with previously treated, HR positive and HER2 negative metastatic breast cancer.

According to a statement released by Pfizer, there are approximately 3,200 women in England living with this specific type of cancer who could now be eligible for the treatment.

Pfizer’s drug can be used to treat patients who have already had earlier rounds of hormone therapy for their advanced disease, and is an important additional treatment for women who may have limited options.

“This outcome marks a significant milestone for the secondary breast cancer community. We know how important it is for women to have access to treatment options that can delay the progression of their disease and help them live a normal life for longer, and we are delighted that through the CDF this option will be available,” said Olivia Ashman, oncology medical director, Pfizer UK.

The CDK 4/6 inhibitor is designed to halt tumour cell growth and delay progression, and is the first oncology therapy that increases the effect of aromatase inhibitors to do so.

It originally scored approval in the EU in November 2016, for the treatments of hormone receptor positive, HER-2 negative, locally advanced metastatic breast cancer.

NICE initially ruled that Ibrance was not a cost-effective use of NHS resources, and said that while Ibrance has been shown to stall disease progression for an average of 10 months more than traditional treatment standard, more clinical evidence was required to quantify overall survival improvement.

However, it then re-considered its decision after Pfizer submitted an ‘improved patient access scheme’, and approved Ibrance for the first-line treatment of advanced breast cancer on combination with an aromatase inhibitor in women with hormone receptor-positive, HER-2 negative tumours.

“This class of medicine remains one of the most important breakthroughs in breast cancer in the last two decades and palbociclib has been shown to slow tumour growth and maintain quality of life, both of which are incredibly important to women living with this type of breast cancer,” said Nicholas Turner, professor of molecular oncology at The Institute of Cancer Research, London and consultant medical oncologist at The Royal Marsden NHS Foundation Trust.

“Today’s news will be warmly welcomed by patients and doctors alike,” he added.

Article by
Lucy Parsons

28th November 2019

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Behavioural Science in Healthcare
Personal health and wellbeing has never been more a part of the public conscious than it is now....
Why aren't doctors using digital therapeutics?
The digital therapeutics market is set to reach almost $1 billion by 2026 as wearables and apps continue to play an important role in enhancing healthcare. However, adoption of these...
Dec PME cover
Creativity in storytelling: why pharma must invest more in creativity
Chris Ross explores the value, the art and the much-rumoured death of creativity...

Infographics